Boston Scientific scores solid results for TAVR device; JenaValve nails down expanded CE mark;

@FierceMedDev: Special Report: 'Big' med tech M&A deals getting smaller. Feature | Follow @FierceMedDev

@DamianFierce: VisionCare landed up to $15M to market its AMD-treating eye implant. News | Follow @DamianFierce

@MarkHFierce: The U.S. will now have the first permanent implant designed to treat enlarged prostates. Expect a gradual launch. ICYMI yesterday | Follow @MarkHFierce

@MichaelGFierce: Abbott snags CE mark for diabetes monitor. Item | Follow @MichaelGFierce

> Boston Scientific ($BSX) reported solid 6-month results for its Lotus device, the company's entrée into transcatheter aortic valve replacement. More

> Salt Lake City's Vital Access scored FDA clearance for its VWing Vascular Needle Guide, designed for hemodialysis procedures. News

> Philips ($PHG) has raised financial targets for most of its units, counting on its banner medical device business to deliver between 4% and 6% sales growth. Article

> In nonrandomized trials, renal denervation has demonstrated significant reductions in blood pressure among hypertensive patients, but those results are likely to come back down to earth in a randomized study, some researchers say. Story

> JenaValve in Germany nailed down an expanded CE mark to use its transcapical TAVI system to treat aortic regurgitation. More

> SpineGuard landed Japanese regulatory approval for a new handheld surgical product that helps guide proper spine screw placement. Item

> The Mayo Clinic is celebrating its 1,000th cochlear implant over 30 years. Item

Biotech News

@FierceBiotech: ICYMI yesterday: CDC director warns antibiotics pipeline 'nearly empty.' Story | Follow @FierceBiotech

@JohnCFierce: Regado CEO moves the goal line after a rare biotech IPO misfire. More | Follow @JohnCFierce

> Biotechs keep the cash pumping (for now) with more IPOs and ATMs. Story

> On a roll, Boehringer wins 'breakthrough' status for pioneering leukemia drug. News

> Broker's Facebook rant on biotech stock draws $5K fine. Item

Pharma News

@FiercePharma: Now armed with EU nod for Lemtrada, Sanofi preps to launch its multiple sclerosis duo (with Aubagio). Release (PDF) | Follow @FiercePharma

@CarlyHFierce: Whistleblower codenamed Zorro implicates Novartis' Alcon division in Chinese bribery scandal. More from The Financial Times | Follow @CarlyHFierce

> Novartis faces second set of bribery claims in China. More

> FDA approves Teva's generic of Roche blockbuster Xeloda. Article

Pharma Manufacturing News

@EricPFierce: Now that Ranbaxy's Mohali plant falls under FDA consent decree, oversight ramps up significantly. Article | Follow @EricPFierce

> Cargill invests $15M in French alginate plant. Item

> Hospira recalls bupivacaine because of steel particles in vials. Story

> Strides gets FDA warning for plant Mylan is buying. More

> J&J sues Ben Venue over Doxil shortage. Report

Biotech Research News

@EmilyMFierce: Initial focus of BRAIN Initiative laid out, but are the goals any clearer than they were in April? Check out the story and weigh in | Follow @EmilyMFierce

> Visterra antibody shows promise in preclinical study as universal flu vaccine. Item

> NIH partners with Eli Lilly, others on rare diseases. Article

> Experimental vaccine clears monkeys of HIV-like virus. More

> Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. Story